Cancer clinical trials cooperative group
Appears in 1 story
Partner on EA2251 international trial
Patients with advanced biliary tract cancer lived a median of 14.9 months on ivonescimab plus chemotherapy, versus 12.1 months on the current standard—a 25% reduction in the risk of death. The results, presented October 25 at the ESMO 2026 Presidential Symposium in Madrid, came from HARMONi-GI1, a Phase III trial conducted entirely in China that pitted the bispecific antibody against durvalumab (Imfinzi) plus chemo.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
